Multiple System Atrophy Market Size

  • Report ID: 3440
  • Published Date: Dec 26, 2024
  • Report Format: PDF, PPT

Multiple System Atrophy Market Size

Multiple System Atrophy (MSA) Market size was valued at USD 145.67 million in 2024 and is likely to cross USD 258.16 million by 2037, registering more than 4.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of multiple system atrophy is estimated at USD 151.24 million.

The growth of the market can be attributed to the growing occurrence of multiple system atrophy across the world, significant shift in people’s lifestyles globally, and rising consumption of alcohol and narcotics. As per the data provided by the Rare Diseases organization, the incidence of multiple system atrophy in the United States alone is 0.6 cases per 100,000 people every year. An estimated 1,900 new cases of the disease occur each year in the country. In addition to these, increasing research and development activities to develop an effective treatment for systemic atrophies and rise in healthcare expenditure in developed and developing nations are also expected to drive growth for the market in the upcoming years. Furthermore, high exposure of people to environmental toxins is projected to offer ample growth opportunities to the market in the near future.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3440
  • Published Date: Dec 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of multiple system atrophy is estimated at USD 151.24 million.

Multiple System Atrophy (MSA) Market size was valued at USD 145.67 million in 2024 and is likely to cross USD 258.16 million by 2037, registering more than 4.5% CAGR during the forecast period i.e., between 2025-2037.

Asia Pacific industry is expected to dominate majority revenue share by 2037, on the back of increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region.

The major players in the market are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample